<SEC-DOCUMENT>0000313143-18-000043.txt : 20180712
<SEC-HEADER>0000313143-18-000043.hdr.sgml : 20180712
<ACCEPTANCE-DATETIME>20180712075537
ACCESSION NUMBER:		0000313143-18-000043
CONFORMED SUBMISSION TYPE:	DEFA14A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20180712
DATE AS OF CHANGE:		20180712
EFFECTIVENESS DATE:		20180712

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HAEMONETICS CORP
		CENTRAL INDEX KEY:			0000313143
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				042882273
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			0328

	FILING VALUES:
		FORM TYPE:		DEFA14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14041
		FILM NUMBER:		18949667

	BUSINESS ADDRESS:	
		STREET 1:		400 WOOD RD
		CITY:			BRAINTREE
		STATE:			MA
		ZIP:			02184
		BUSINESS PHONE:		7818487100

	MAIL ADDRESS:	
		STREET 1:		400 WOOD ROAD
		CITY:			BRAINTREE
		STATE:			MA
		ZIP:			02184
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEFA14A
<SEQUENCE>1
<FILENAME>hae-defa14a2018.htm
<DESCRIPTION>DEFA14A
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2018 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sEF39823A562873A76000E092060165B0"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">WASHINGTON, DC 20549</font></div><div style="line-height:144%;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><div style="line-height:144%;text-align:center;font-size:15pt;"><font style="font-family:Arial;font-size:15pt;font-weight:bold;">SCHEDULE 14A</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:9pt;">&#160;</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Proxy Statement Pursuant to Section 14(a)</font></div><div style="line-height:144%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">of the Securities Exchange Act of 1934</font></div><div style="line-height:120%;padding-bottom:9px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:88.50574712643679%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Filed by the Registrant&#160;</font><font style="font-family:inherit;font-size:9pt;">&#9746;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Filed by a Party other than the Registrant&#160;</font><font style="font-family:inherit;font-size:9pt;">&#9744;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:9px;padding-top:2px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.272030651341%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Check the appropriate box:</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#9744;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;Preliminary Proxy Statement</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#9744;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#9744;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;Definitive Proxy Statement</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#9746;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#160;Definitive Additional Materials</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#9744;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;padding-top:2px;padding-left:4px;font-size:10pt;"><font style="font-family:Arial;font-size:9pt;">&#160;Soliciting Material under </font><font style="font-family:inherit;font-size:10pt;">&#167;</font><font style="font-family:Arial;font-size:9pt;">240.14a-12</font></div></td></tr></table></div></div><div style="line-height:144%;padding-top:18px;text-align:center;"><img src="hae2018defa14a_image1.gif" alt="hae2018defa14a_image1.gif" style="height:61px;width:220px;"></div><div style="line-height:144%;padding-top:16px;text-align:center;font-size:15pt;"><font style="font-family:Arial;font-size:15pt;font-weight:bold;">HAEMONETICS CORPORATION</font></div><div style="line-height:120%;padding-bottom:25px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">(Name of Registrant as Specified in Its Charter)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:89.272030651341%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:6%;"></td><td style="width:94%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Payment of Filing Fee (Check the appropriate box):</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#9746;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">No fee required.</font></div></td></tr><tr><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#9744;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and&#160;0-11.</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:2px;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1)  Title of each class of securities to which transaction applies:</font></div><div style="padding-bottom:4px;padding-top:4px;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(2)  Aggregate number of securities to which transaction applies:</font></div><div style="padding-bottom:4px;padding-top:4px;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(3)  Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):</font></div><div style="padding-bottom:4px;padding-top:4px;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(4)  Proposed maximum aggregate value of transaction:</font></div><div style="padding-bottom:2px;padding-top:4px;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(5)  Total fee paid:</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#9744;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Fee paid previously with preliminary materials.</font></div></td></tr><tr><td rowspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;">&#9744;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:2px;text-align:left;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="padding-bottom:4px;padding-top:2px;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(1)  Amount Previously Paid:</font></div><div style="padding-bottom:4px;padding-top:4px;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(2)  Form, Schedule or Registration Statement No.:</font></div><div style="padding-bottom:4px;padding-top:4px;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(3)  Filing Party:</font></div><div style="padding-bottom:2px;padding-top:4px;padding-left:4px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(4)  Date Filed:</font></div></td></tr></table></div></div><div style="line-height:144%;padding-bottom:10px;padding-top:2px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="s813f0091a7da41ffbd886310765c99cb"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:144%;padding-top:18px;text-align:left;"><img src="hae2018defa14a_image1.gif" alt="hae2018defa14a_image1.gif" style="height:61px;width:220px;"></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Haemonetics Corporation Supplemental Proxy Materials</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">For the Annual Meeting of Shareholders to be Held on July 26, 2018</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">July 12, 2018</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dear Shareholder:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On July 26, 2018, we will hold our 2018 Annual Meeting of Shareholders (the &#8220;Meeting&#8221;). We ask for your support by voting as our Board of Directors (the &#8220;Board&#8221;) recommends on each of the proposals at the Meeting, which are more fully described in the proxy statement previously made available to you on or about June 12, 2018. </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">In particular, we request that you vote </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">FOR</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;the election of each of Catherine M. Burzik, Richard J. Meelia and Ronald G. Gelbman as directors (Item 1) and </font><font style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">FOR</font><font style="font-family:Arial;font-size:10pt;font-weight:bold;">&#32;the proposal to amend our Restated Articles of Organization (the &#8220;Charter&#8221;) and By-Laws to reduce certain super-majority voting requirements to a majority voting standard (Item 4).  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In further support of our Board&#8217;s recommendations that you vote </font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">FOR</font><font style="font-family:Arial;font-size:10pt;">&#32;Items 1 and 4, we ask that you consider the following points in addition to the statements previously made in the proxy statement: </font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Massachusetts Corporation Law</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Haemonetics is incorporated under the laws of The Commonwealth of Massachusetts. Under Massachusetts law, the minimum voting threshold permitted to amend the articles of organization of a Massachusetts corporation is a majority of shares entitled to vote on the matter. Accordingly, the proposal in Item 4 to change certain voting requirements in our Charter from a super-majority (80%) to a majority of our outstanding shares is the lowest voting threshold permitted under Massachusetts law.   </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Commitment to Good Corporate Governance and Shareholder Engagement</font></div><div style="line-height:120%;text-align:left;padding-left:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our Board, with the leadership of our Governance and Compliance Committee, pursues continuous improvements in Haemonetics&#8217; corporate governance by monitoring recent developments in law and current governance best practices. Following the 2017 Annual Meeting of Shareholders, the Governance and Compliance Committee undertook a comprehensive evaluation of Haemonetics&#8217; governance policies and practices, and our Board has authorized a number of recent governance improvements as an output of this review (see page 6 of the proxy statement for further discussion). We also meet regularly with our shareholders and value their input regarding our business plans and corporate governance. In the past 12 months, senior members of management and our investor-relations team held approximately 70 meetings with shareholders of Haemonetics (including a majority of our 25 largest shareholders) to hear from them regarding topics of shareholder interest. </font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Our Board intended that the proposed amendments to our Charter and By-Laws in Item 4 of our proxy statement be highly responsive to the shareholder proposal presented at our 2017 Annual Meeting of Shareholders, and we believe the proposal as set forth in Item 4 is consistent with prevailing governance practices and in the long-term best interests of Haemonetics and its shareholders. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We ask that you vote </font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">FOR</font><font style="font-family:Arial;font-size:10pt;">&#32;the election of each of Catherine M. Burzik, Richard J. Meelia and Ronald G. Gelbman as directors (Item 1) and </font><font style="font-family:Arial;font-size:10pt;text-decoration:underline;">FOR</font><font style="font-family:Arial;font-size:10pt;">&#32;the proposal to amend our Charter and By-Laws to reduce certain super-majority voting requirements to a majority voting standard (Item 4). We thank you for your consideration and continued support of Haemonetics.  </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Copies of Haemonetics&#8217; proxy statement (including any amendments or supplements thereto) and Annual Report to Shareholders for the fiscal year ended March 31, 2018 are available at www.edocumentview.com/HAE and on the Investor Relations page on Haemonetics&#8217; website at www.haemonetics.com. Printed copies can be obtained by contacting our Corporate Secretary at Haemonetics' registered office located at 400 Wood Road, Braintree, Massachusetts 02184</font><font style="font-family:Arial;font-size:10pt;">.</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>hae2018defa14a_image1.gif
<TEXT>
begin 644 hae2018defa14a_image1.gif
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M;3EID@8T-\W(\;8HYX45!"C@X1"/^%>$K&DB%X10A(8S+,$20'@/4M(2H3#
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5S- <S=(\S=1<S=9\S=B<S2 1$  [

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
